期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 19, 期 47, 页码 8850-8860出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v19.i47.8850
关键词
Reprogramming; Hepatocellular carcinomas; Cancer stem cells; Transcription factor; Therapeutics
资金
- Ministry of Education, Culture, Sports, Science and Technology of Japan [18591421, 20591531, 23591872]
- Research Center Network for Realization of Regenerative Medicine
- Japan Science and Technology Agency [62890004]
- Grants-in-Aid for Scientific Research [18591421, 23591872, 20591531, 62890004] Funding Source: KAKEN
Hepatocellular carcinoma (HCC) is one of the most common cancers, and is also the leading cause of death worldwide. Studies have shown that cellular reprogramming contributes to chemotherapy and/or radiotherapy resistance and the recurrence of cancers. In this article, we summarize and discuss the latest findings in the area of cellular reprogramming in HCC. The aberrant expression of transcription factors OCT4, KLF4, SOX2, c-MYC, NANOG, and LIN28 have been also observed, and the expression of these transcription factors is associated with unfavorable clinical outcomes in HCC. Studies indicate that cellular reprogramming may play a critical role in the occurrence and recurrence of HCC. Recent reports have shown that DNA methylation, miRNAs, tumor microenvironment, and signaling pathways can induce the expression of stemness transcription factors, which leads to cellular reprogramming in HCC. Furthermore, studies indicate that therapies based on cellular reprogramming could revolutionize HCC treatment. Finally, a novel therapeutic concept is discussed: reprogramming control therapy. A potential reprogramming control therapy method could be developed based on the reprogramming demonstrated in HCC studies and applied at two opposing levels: differentiation and reprogramming. Our increasing understanding and control of cellular programming should facilitate the exploitation of this novel therapeutic concept and its application in clinical HCC treatment, which may represent a promising strategy in the future that is not restricted to liver cancer. (C) 2013 Baishideng Publishing Group Co., Limited. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据